Company registration number 09377104 (England and Wales)
ENFERM MEDICAL LTD.
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024
PAGES FOR FILING WITH REGISTRAR
ENFERM MEDICAL LTD.
CONTENTS
Page
Accountants' report
1
Balance sheet
2 - 3
Notes to the financial statements
4 - 7
ENFERM MEDICAL LTD.
CHARTERED ACCOUNTANTS' REPORT TO THE DIRECTOR ON THE PREPARATION OF THE UNAUDITED STATUTORY FINANCIAL STATEMENTS OF ENFERM MEDICAL LTD. FOR THE YEAR ENDED 31 DECEMBER 2024
- 1 -

In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the financial statements of Enferm Medical Ltd. for the year ended 31 December 2024 which comprise, the balance sheet and the related notes from the company’s accounting records and from information and explanations you have given us.

 

As a practising member firm of the Institute of Chartered Accountants in England and Wales (ICAEW), we are subject to its ethical and other professional requirements which are detailed at https://www.icaew.com/regulation.

This report is made solely to the board of directors of Enferm Medical Ltd., as a body, in accordance with the terms of our engagement letter dated 18 February 2024. Our work has been undertaken solely to prepare for your approval the financial statements of Enferm Medical Ltd. and state those matters that we have agreed to state to the board of directors of Enferm Medical Ltd., as a body, in this report in accordance with ICAEW Technical Release 07/16 AAF. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than Enferm Medical Ltd. and its board of directors as a body, for our work or for this report.

It is your duty to ensure that Enferm Medical Ltd. has kept adequate accounting records and to prepare statutory financial statements that give a true and fair view of the assets, liabilities, financial position and loss of Enferm Medical Ltd.. You consider that Enferm Medical Ltd. is exempt from the statutory audit requirement for the year.

We have not been instructed to carry out an audit or a review of the financial statements of Enferm Medical Ltd.. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory financial statements.

Carpenter Box
30 May 2025
Chartered Accountants
5 Peveril Court
6-8 London Road
Crawley
West Sussex
RH10 8JE
ENFERM MEDICAL LTD.
BALANCE SHEET
AS AT 31 DECEMBER 2024
31 December 2024
- 2 -
2024
2023
Notes
£
£
£
£
Fixed assets
Intangible assets
3
313,758
504,475
Tangible assets
4
8,135
20,698
321,893
525,173
Current assets
Debtors
5
561,416
1,195,390
Cash at bank and in hand
65,443
1,977
626,859
1,197,367
Creditors: amounts falling due within one year
6
(1,441,826)
(1,810,072)
Net current liabilities
(814,967)
(612,705)
Total assets less current liabilities
(493,074)
(87,532)
Creditors: amounts falling due after more than one year
7
(69,331)
(135,813)
Net liabilities
(562,405)
(223,345)
Capital and reserves
Called up share capital
8
100
100
Profit and loss reserves
(562,505)
(223,445)
Total equity
(562,405)
(223,345)

The director of the company has elected not to include a copy of the profit and loss account within the financial statements.true

For the financial year ended 31 December 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

ENFERM MEDICAL LTD.
BALANCE SHEET (CONTINUED)
AS AT 31 DECEMBER 2024
31 December 2024
- 3 -
The financial statements were approved and signed by the director and authorised for issue on 30 May 2025
Mr J A Sprigg
Director
Company registration number 09377104 (England and Wales)
ENFERM MEDICAL LTD.
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024
- 4 -
1
Accounting policies
Company information

Enferm Medical Ltd. is a private company limited by shares incorporated in England and Wales. The registered office is Elder House West, Elder Gate, Milton Keynes, Buckinghamshire, England, MK9 1LR.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2
Going concern

At the time of approving the financial statements, the director has a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. The director has considered relevant information, including the company’s principal risks and uncertainties, and the impact of subsequent events in making their assessment. true

 

At the balance sheet date the company is in a net liabilities position. The company is reliant on the ongoing support of its director and is meeting its liabilities as they fall due. The financial statements do not include any adjustments that would result in the withdrawal of their support.

 

Based on these assessments and having regard to the resources available to the entity, the director has concluded that there is no material uncertainty and that they can continue to adopt the going concern basis in preparing the annual report and financial statements.

1.3
Turnover

Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.

1.4
Intangible fixed assets other than goodwill

Intangible assets acquired separately from a business are recognised at cost and are subsequently measured at cost less accumulated amortisation and accumulated impairment losses.

Amortisation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Computer software
33% straight line per annum
1.5
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

ENFERM MEDICAL LTD.
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
1
Accounting policies
(Continued)
- 5 -

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Plant and equipment
20% diminishing balance per annum
Fixtures and fittings
25% & 33% straight line per annum
Computers
33% straight line per annum
1.6
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.7
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost.

Basic financial liabilities

Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

1.8
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

1.9
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year.

1.10
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

2
Employees

The average monthly number of persons (including directors) employed by the company during the year was 25 (2023 - 31).

ENFERM MEDICAL LTD.
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 6 -
3
Intangible fixed assets
Computer software
£
Cost
At 1 January 2024 and 31 December 2024
572,150
Amortisation and impairment
At 1 January 2024
67,675
Amortisation charged for the year
190,717
At 31 December 2024
258,392
Carrying amount
At 31 December 2024
313,758
At 31 December 2023
504,475
4
Tangible fixed assets
Plant and equipment
Fixtures and fittings
Computers
Total
£
£
£
£
Cost
At 1 January 2024
5,460
26,229
34,087
65,776
Additions
-
0
-
0
3,160
3,160
At 31 December 2024
5,460
26,229
37,247
68,936
Depreciation and impairment
At 1 January 2024
4,251
14,887
25,940
45,078
Depreciation charged in the year
242
8,534
6,947
15,723
At 31 December 2024
4,493
23,421
32,887
60,801
Carrying amount
At 31 December 2024
967
2,808
4,360
8,135
At 31 December 2023
1,209
11,342
8,147
20,698
5
Debtors
2024
2023
Amounts falling due within one year:
£
£
Trade debtors
448,936
796,730
Other debtors
112,480
398,660
561,416
1,195,390
ENFERM MEDICAL LTD.
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 7 -
6
Creditors: amounts falling due within one year
2024
2023
£
£
Bank loans and overdrafts
28,200
61,608
Trade creditors
212,783
737,721
Amounts owed to group undertakings
2,500
2,500
Taxation and social security
598,245
316,285
Other creditors
600,098
691,958
1,441,826
1,810,072

Included within other creditors is £281,137 (2023: £362,186) due payable under invoice discounting contracts.

These amounts are secured against the discounted invoices.

 

Included within other creditors is £47,672 (2023: £nil) owed to a connected company. The balance is interest free and repayable on demand.

7
Creditors: amounts falling due after more than one year
2024
2023
£
£
Bank loans and overdrafts
-
0
135,813
Other creditors
69,331
-
0
69,331
135,813

The bank loan accrued interest at a rate of 3.4% above base rate per annum. The loan was fully repaid during the year.

 

Other creditors relates to a loan from a connected partnership. The loan is interest free and is repayable in instalments. The loan is due to be fully repaid by August 2027.

8
Called up share capital
2024
2023
2024
2023
Ordinary share capital
Number
Number
£
£
Issued and fully paid
Ordinary shares of 10p each
1,000
1,000
100
100
2024-12-312024-01-01falsefalsefalse30 May 2025CCH SoftwareCCH Accounts Production 2025.100No description of principal activityMr J A Sprigg093771042024-01-012024-12-31093771042024-12-31093771042023-12-3109377104core:IntangibleAssetsOtherThanGoodwill2024-12-3109377104core:IntangibleAssetsOtherThanGoodwill2023-12-3109377104core:PlantMachinery2024-12-3109377104core:FurnitureFittings2024-12-3109377104core:ComputerEquipment2024-12-3109377104core:PlantMachinery2023-12-3109377104core:FurnitureFittings2023-12-3109377104core:ComputerEquipment2023-12-3109377104core:CurrentFinancialInstrumentscore:WithinOneYear2024-12-3109377104core:CurrentFinancialInstrumentscore:WithinOneYear2023-12-3109377104core:Non-currentFinancialInstrumentscore:AfterOneYear2024-12-3109377104core:Non-currentFinancialInstrumentscore:AfterOneYear2023-12-3109377104core:CurrentFinancialInstruments2024-12-3109377104core:CurrentFinancialInstruments2023-12-3109377104core:Non-currentFinancialInstruments2024-12-3109377104core:Non-currentFinancialInstruments2023-12-3109377104core:ShareCapital2024-12-3109377104core:ShareCapital2023-12-3109377104core:RetainedEarningsAccumulatedLosses2024-12-3109377104core:RetainedEarningsAccumulatedLosses2023-12-3109377104core:ShareCapitalOrdinaryShareClass12024-12-3109377104core:ShareCapitalOrdinaryShareClass12023-12-3109377104bus:Director12024-01-012024-12-3109377104core:IntangibleAssetsOtherThanGoodwill2024-01-012024-12-3109377104core:ComputerSoftware2024-01-012024-12-3109377104core:PlantMachinery2024-01-012024-12-3109377104core:FurnitureFittings2024-01-012024-12-3109377104core:ComputerEquipment2024-01-012024-12-31093771042023-01-012023-12-3109377104core:IntangibleAssetsOtherThanGoodwill2023-12-3109377104core:PlantMachinery2023-12-3109377104core:FurnitureFittings2023-12-3109377104core:ComputerEquipment2023-12-31093771042023-12-3109377104core:WithinOneYear2024-12-3109377104core:WithinOneYear2023-12-3109377104bus:OrdinaryShareClass12024-01-012024-12-3109377104bus:OrdinaryShareClass12024-12-3109377104bus:OrdinaryShareClass12023-12-3109377104bus:PrivateLimitedCompanyLtd2024-01-012024-12-3109377104bus:SmallCompaniesRegimeForAccounts2024-01-012024-12-3109377104bus:FRS1022024-01-012024-12-3109377104bus:AuditExemptWithAccountantsReport2024-01-012024-12-3109377104bus:FullAccounts2024-01-012024-12-31xbrli:purexbrli:sharesiso4217:GBP